Closed Loop Medicine (CLM) has announced the US launch of WeDosify, which enables clinicians to personalise GLP-1 titration at scale.
The launch comes as the global anti-obesity market, valued at over $30bn in 2024, is projected to reach $100bn by 2030.
Despite this growth, GLP-1 therapies face a major real-world challenge: up to 44% of patients discontinue treatment within six months, with that figure rising to 60% within 12 months.
This drop in adherence is often due to dose-related gastrointestinal side effects such as nausea, vomiting and diarrhoea.
It can also be from a lack of support for how these medicines should be used longer term to achieve and then maintain weight loss.
Many patients are self-adjusting doses without medical supervision, further limiting long-term treatment success.
WeDosify addresses these challenges by presenting individualised dosing options for clinical review, based on tolerability, treatment goals and clinical data.
These are then adapted over time based on the individual’s response to the drug.
The platform enables healthcare providers, telehealth companies and health systems to make informed titration decisions using the best available evidence and maintain patients on effective therapy for longer.
Ninety-one per cent of GLP-1 patients surveyed agreed or strongly agreed that they would be more likely to stay on treatment if they had the support of WeDosify.
"Having data helps you make personalised decisions and makes you more engaged with your weight loss journey" – anonymous patient surveyed.
The solution draws on 29 clinical studies and over 15,000 patient profiles, supported by advanced pharmacokinetic/pharmacodynamic (PK/PD) modelling.
In hypertension trials, CLM’s dosing technology delivered better treatment outcomes, fewer side effects and exceptional adherence — a track record now applied to GLP-1 therapies for the first time.
Amarillo Premier Research, an ObjectiveHealth network site in Texas, is already beginning use of WeDosify this week.
Dr Neese, Clinician, Texas, commented: “I am delighted to have the opportunity to share WeDosify with my patients."
"It will enable me to work with each patient to determine a course of action that is genuinely personal to them, helping them to achieve lasting weight loss.”
The launch marks a major milestone for CLM as it rolls out its first commercially available product to clinicians and patients in the US.
It builds on a differentiated foundation of intellectual property and clinical data as the company focusses on driving more effective, patient-centric care.
WeDosify supports the goals of the Right Drug Dose Now Act by enabling drug manufacturers and distributors to offer safer, more effective treatments through precision prescribing, reducing adverse drug events.
Enhancing drug therapeutic profiles enables premium pricing and unlocks new revenue streams at a critical time when US policies may severely limit direct-to-patient pharmaceutical advertisements.
The platform enables real-time simulations and reporting, supporting the White House’s HTI-4 initiative to advance patient-centric digital healthcare.
Kate Woolland, CEO of Closed Loop Medicine, said: "We are seeing an increasing number of companies trying to offer more personalised services to support patients on GLP-1 therapies, but the actual level of personalisation is very limited and early results are showing little impact on overall patient discontinuations.”
“WeDosify is the first product that offers genuinely personalised recommendations which update in real time to reflect how the patient is responding to the drug."
"For the first time, patients can see what their weight loss journey might look like and work alongside their clinician to make decisions about their health."
"This is a genuine game-changer and a crucial step in realising our mission to make personalised care accessible to all.”